Drug intelligence / Profile preview

pantoprazole + famotidine

Development stage: Preclinical
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination of two acid-reducing medications that work through different mechanisms. Pantoprazole is a proton pump inhibitor (PPI) that blocks acid production by irreversibly binding to the (H+, K+)-ATPase enzyme in gastric parietal cells. Famotidine is a histamine-2 (H2) receptor antagonist that reduces stomach acid by blocking histamine signals. This combination is not typically recommended for routine use due to overlapping effects, but may be prescribed in specific clinical situations such as severe acid hypersecretion, breakthrough symptoms, or when transitioning between medications.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)HRH2 (Histamine H2 Receptor)

Beyond the preview

Go deeper on pantoprazole + famotidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pantoprazole + famotidine.

Explore the full profile